FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Marc Wirden

Research Profile

Living Beings

HIV-1

Disorders

HIV Infections

Physiology

Chemicals & Drugs

Concepts & Ideas

Procedures

Co-author Network

Publications

TOP 3
Lambert Assoumou; Marie-Laure Chaix; Dominique Costagliola; Constance Delaugerre; Diane Descamps; Georges Dos Santos; Jacques Izopet; Anne-Geneviève Marcelin; Bernard Masquelier; Brigitte Montes; Laurence Morand-Joubert; Sophie Pakianather; Jean-Christophe Plantier; Annick Ruffault; Marc Wirden; Sabine Yerly
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
S Lambert-Niclot; Vincent Calvez; C Charpentier; Diane Descamps; Philippe Flandre; D B Fofana; S Fourati; Bernard Masquelier; Laurence Morand-Joubert; Cathia Soulié; A Storto; B Visseaux; Marc Wirden; Anne-Geneviève Marcelin
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
Marc Wirden; Manuela Bonmarchand; Vincent Calvez; Slim Fourati; Christine Katlama; Nadine Ktorza; Luminita Schneider; Anne Simon; Cathia Soulié; Roland Tubiana; Marc-Antoine Valantin; Anne-Geneviève Marcelin
Pitfalls of HIV genotypic tropism testing after treatment interruption.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Marc Wirden (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Lambert Assoumou; Marie-Laure Chaix; Dominique Costagliola; Constance Delaugerre; Diane Descamps; Georges Dos Santos; Jacques Izopet; Anne-Geneviève Marcelin; Bernard Masquelier; Brigitte Montes; Laurence Morand-Joubert; Sophie Pakianather; Jean-Christophe Plantier; Annick Ruffault; Marc Wirden; Sabine Yerly
Prevalence of HIV-1 drug resistance in treated patients with viral load >50 copies/mL in 2009: a French nationwide study.
The Journal of antimicrobial chemotherapy 2013;68(6):1400-5.
2013: S Lambert-Niclot; Vincent Calvez; C Charpentier; Diane Descamps; Philippe Flandre; D B Fofana; S Fourati; Bernard Masquelier; Laurence Morand-Joubert; Cathia Soulié; A Storto; B Visseaux; Marc Wirden; Anne-Geneviève Marcelin
Prevalence of pre-existing resistance-associated mutations to rilpivirine, emtricitabine and tenofovir in antiretroviral-naive patients infected with B and non-B subtype HIV-1 viruses.
The Journal of antimicrobial chemotherapy 2013;68(6):1237-42.
2013: Marc Wirden; Manuela Bonmarchand; Vincent Calvez; Slim Fourati; Christine Katlama; Nadine Ktorza; Luminita Schneider; Anne Simon; Cathia Soulié; Roland Tubiana; Marc-Antoine Valantin; Anne-Geneviève Marcelin
Pitfalls of HIV genotypic tropism testing after treatment interruption.
The Journal of antimicrobial chemotherapy 2013;68(1):188-9.
2012: Isabelle Malet; Vincent Calvez; Philippe Flandre; Slim Fourati; Pierre-Marie Girard; Stéphanie Haim-Boukobza; Christine Katlama; Laurence Morand-Joubert; Theresa Pattery; Sophie Sayon; Anne Simon; Marc Wirden; Anne-Geneviève Marcelin
Risk factors for raltegravir resistance development in clinical practice.
The Journal of antimicrobial chemotherapy 2012;67(10):2494-500.
2012: Slim Fourati; Christine Katlama; Sidonie Lambert; Isabelle Malet; Sophie Sayon; Anne Simon; Cathia Soulie; Marc Wirden; Vincent Calvez; Philippe Flandre; Djeneba B Fofana; Anne-Geneviève Marcelin
E138K and M184I mutations in HIV-1 reverse transcriptase coemerge as a result of APOBEC3 editing in the absence of drug exposure.
AIDS (London, England) 2012;26(13):1619-24.
2012: DAVID BOUTOLLEAU; Sonia Burrel; Ana Canestri; Cyril Clavel-Osorio; Christine Katlama; Anne-Geneviève Marcelin; Sophie Seang; Marc Wirden; Henri Agut
Emergence of cytomegalovirus resistance to foscarnet in a patient receiving foscarnet salvage therapy for multidrug-resistant HIV infection.
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology 2012;54(2):194-6.
2012: Anne-Geneviève Marcelin; Anne Simon; Marc-Antoine Valantin; Marc Wirden; Patrick Yeni; Charlotte Charpentier; Diane Descamps; Christine Katlama; Roland Landman; Camille Aubron-Olivier; Vincent Calvez
Resistance profiles of emtricitabine and lamivudine in tenofovir-containing regimens.
The Journal of antimicrobial chemotherapy 2012;67(6):1475-8.
2012: Ruxandra Calin; Rachid Agher; Luc Paris; Gilles Peytavin; Luminita Schneider; Anne Simon; Roland Tubiana; Marc-Antoine Valantin; Marc Wirden; Christine Katlama
Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy.
Antiviral therapy 2012;17(8):1601-4.
2012: Sidonie Lambert-Niclot; Laurence Bocket; Vincent Calvez; Georges DOS SANTOS; Philippe Flandre; Slim Fourati; Christine Katlama; Bernard Masquelier; Sophie Pakianather; Sophie Sayon; Cathia Soulie; Marc-Antoine Valantin; Marc Wirden; Anne-Genevieve Marcelin
Similar evolution of cellular HIV-1 DNA level in darunavir/ritonavir monotherapy versus triple therapy in MONOI-ANRS136 trial over 96 weeks.
PloS one 2012;7(7):e41390.
2011: Isabelle Malet; Laurence Morand-Joubert; Carlo Federico Perno; Sophie Sayon; Margriet Van Houtte; Marc Wirden; Daniele Armenia; Françoise Brun-Vézinet; Vincent Calvez; André Capt; Francesca Ceccherini-Silberstein; Charlotte Charpentier; Diane Descamps; Slim Fourati; Anne-Geneviève Marcelin
The HIV-1 integrase G118R mutation confers raltegravir resistance to the CRF02_AG HIV-1 subtype.
The Journal of antimicrobial chemotherapy 2011;66(12):2827-30.
2011: Marc Wirden; Zaina Ait-Arkoub; Ana Canestri; S Fourati; Christine Katlama; Anne-Geneviève Marcelin; Anne Simon; C Soulie; M Thevenin; Roland Tubiana; Vincent Calvez
Upgraded Cobas Ampliprep-Cobas TaqMan version 2.0 HIV-1 RNA quantification assay versus first version: correction of underestimations.
Journal of clinical microbiology 2011;49(7):2700-2.
2011: Isabelle Malet; Anne-Geneviève Marcelin; Bernard Masquelier; Carlo Federico Perno; Sophie Sayon; Marc Wirden; Daniele Armenia; Vincent Calvez; Lavinia Fabeni; Slim Fourati; Christine Katlama; Francesca Ceccherini-Silberstein
Prevalence of resistance mutations related to integrase inhibitor S/GSK1349572 in HIV-1 subtype B raltegravir-naive and -treated patients.
The Journal of antimicrobial chemotherapy 2011;66(7):1481-3.
2011: Marc Wirden; Cathia Soulie; Marc-Antoine Valantin; Slim Fourati; Anne Simon; Sidonie Lambert-Niclot; Manuela Bonmarchand; Cyril Clavel-Osorio; Anne-Geneviève Marcelin; Christine Katlama; Vincent Calvez
Historical HIV-RNA resistance test results are more informative than proviral DNA genotyping in cases of suppressed or residual viraemia.
The Journal of antimicrobial chemotherapy 2011;66(4):709-12.
2011: Lucile Larrouy; Sidonie Lambert-Niclot; Charlotte Charpentier; Slim Fourati; Benoit Visseaux; Cathia Soulié; Marc Wirden; Christine Katlama; Patrick Yeni; Françoise Brun-Vézinet; Vincent Calvez; Anne-Geneviève Marcelin; Diane Descamps
Positive impact of HIV-1 gag cleavage site mutations on the virological response to darunavir boosted with ritonavir.
Antimicrobial agents and chemotherapy 2011;55(4):1754-7.
2011: Cathia Soulie; Sidonie Lambert-Niclot; Marc Wirden; Anne Simon; Marc-Antoine Valantin; Slim Fourati; Roland Tubiana; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Low frequency of HIV-1 tropism evolution in patients successfully treated for at least 2 years.
AIDS (London, England) 2011;25(4):537-9.
2011: Hassane Izzedine; Veena Acharya; Marc Wirden; Philippe Cluzel; Damien Sene; Gregory M Lucas; Alain Baumelou; Mohamed G Atta
Role of HIV-1 DNA levels as clinical marker of HIV-1-associated nephropathies.
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 2011;26(2):580-3.
2010: S Lambert-Niclot; N Machouf; G Peytavin; C Soulie; Marc Wirden; A Simon; R L Murphy; C Katlama; R Thomas; V Calvez; A G Marcelin
Pharmacokinetics, protein-binding-adjusted inhibitory quotients for atazanavir/ritonavir 300/100 mg in treatment-naïve HIV-infected patients.
HIV medicine 2010;11(10):666-9.
2010: Slim Fourati; Isabelle Malet; Mawuena Binka; Stephanie Boukobza; Marc Wirden; Sophie Sayon; Anne Simon; Christine Katlama; Viviana Simon; Vincent Calvez; Anne-Geneviève Marcelin
Partially active HIV-1 Vif alleles facilitate viral escape from specific antiretrovirals.
AIDS (London, England) 2010;24(15):2313-21.
2010: Cathia Soulié; Slim Fourati; Sidonie Lambert-Niclot; Isabelle Malet; Marc Wirden; Roland Tubiana; Marc-Antoine Valantin; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Factors associated with proviral DNA HIV-1 tropism in antiretroviral therapy-treated patients with fully suppressed plasma HIV viral load: implications for the clinical use of CCR5 antagonists.
The Journal of antimicrobial chemotherapy 2010;65(4):749-51.
2010: Philip M Grant; Jonathan Taylor; Andrew B Nevins; Vincent Calvez; Anne-Geneviève Marcelin; Marc Wirden; Andrew R Zolopa
International cohort analysis of the antiviral activities of zidovudine and tenofovir in the presence of the K65R mutation in reverse transcriptase.
Antimicrobial agents and chemotherapy 2010;54(4):1520-5.
2010: Almoustapha Issiaka Maïga; Diane Descamps; Laurence Morand-Joubert; Isabelle Malet; Anne Derache; Mamadou Cisse; Victoria Koita; Alain Akonde; Bah Diarra; Marc Wirden; Anatole Tounkara; Yvan Verlinden; Christine Katlama; Dominique Costagliola; Bernard Masquelier; Vincent Calvez; Anne-Geneviève Marcelin
Resistance-associated mutations to etravirine (TMC-125) in antiretroviral-naïve patients infected with non-B HIV-1 subtypes.
Antimicrobial agents and chemotherapy 2010;54(2):728-33.
2009: Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Isabelle Malet; Hocine Ait Mohand; Gilles Peytavin; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Raltegravir has no residual antiviral activity in vivo against HIV-1 with resistance-associated mutations to this drug.
The Journal of antimicrobial chemotherapy 2009;64(5):1087-90.
2009: Jade Ghosn; Anne-Aurélie Mazet; Véronique Avettand-Fenoel; Gilles Peytavin; Marc Wirden; Jean-François Delfraissy; Marie-Laure Chaix
Rapid selection and archiving of mutation E157Q in HIV-1 DNA during short-term low-level replication on a raltegravir-containing regimen.
The Journal of antimicrobial chemotherapy 2009;64(2):433-4.
2009: Marc Wirden; Roland Tubiana; F Marguet; I Leroy; Anne Simon; Manuela Bonmarchand; Zaina Ait-Arkoub; R Murphy; Anne-Geneviève Marcelin; Christine Katlama; Vincent Calvez
Impact of discrepancies between the Abbott realtime and cobas TaqMan assays for quantification of human immunodeficiency virus type 1 group M non-B subtypes.
Journal of clinical microbiology 2009;47(5):1543-5.
2009: Isabelle Malet; Olivier Delelis; Cathia Soulie; Marc Wirden; Luba Tchertanov; Philippe Mottaz; Gilles Peytavin; Christine Katlama; Jean-François Mouscadet; Vincent Calvez; Anne-Geneviève Marcelin
Quasispecies variant dynamics during emergence of resistance to raltegravir in HIV-1-infected patients.
The Journal of antimicrobial chemotherapy 2009;63(4):795-804.
2009: Marie-Laure Chaix; Diane Descamps; Marc Wirden; Laurence Bocket; Constance Delaugerre; Catherine Tamalet; Veronique Schneider; Jacques Izopet; Bernard Masquelier; Christine Rouzioux; Laurence Meyer; Dominique Costagliola
Stable frequency of HIV-1 transmitted drug resistance in patients at the time of primary infection over 1996-2006 in France.
AIDS (London, England) 2009;23(6):717-24.
2009: Marc Wirden; Sidonie Lambert-Niclot; Anne-Geneviève Marcelin; Luminita Schneider; Hocine Ait Mohand; Christel Brunet; Francis Angleraud; Sylvain Amard; Christine Katlama; Vincent Calvez
Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
AIDS (London, England) 2009;23(1):95-9.
2008: Sidonie Lambert-Niclot; Philippe Flandre; Isabelle Malet; Ana Canestri; Cathia Soulié; Roland Tubiana; Christel Brunet; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Impact of gag mutations on selection of darunavir resistance mutations in HIV-1 protease.
The Journal of antimicrobial chemotherapy 2008;62(5):905-8.
2008: Isabelle Malet; Olivier Delelis; Marc-Antoine Valantin; Brigitte Montes; Cathia Soulie; Marc Wirden; Luba Tchertanov; Gilles Peytavin; Jacques Reynes; Jean-François Mouscadet; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro.
Antimicrobial agents and chemotherapy 2008;52(4):1351-8.
2008: Sidonie Lambert-Niclot; Philippe Flandre; Ana Canestri; Gilles Peytavin; Christine Blanc; Rachid Agher; Cathia Soulié; Marc Wirden; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Factors associated with the selection of mutations conferring resistance to protease inhibitors (PIs) in PI-experienced patients displaying treatment failure on darunavir.
Antimicrobial agents and chemotherapy 2008;52(2):491-6.
2007: Isabelle Malet; Marc Wirden; Anne Derache; Anne Simon; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Primary genotypic resistance of HIV-1 to the maturation inhibitor PA-457 in protease inhibitor-experienced patients.
AIDS (London, England) 2007;21(7):871-3.
2007: Isabelle Malet; Bénédicte Roquebert; Cécile Dalban; Marc Wirden; Bahia Amellal; Rachid Agher; Anne Simon; Christine Katlama; Dominique Costagliola; Vincent Calvez; Anne-Geneviève Marcelin
Association of Gag cleavage sites to protease mutations and to virological response in HIV-1 treated patients.
The Journal of infection 2007;54(4):367-74.
2007: Bénédicte Roquebert; Marc Wirden; Anne Simon; Jérome Deval; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Relationship between mutations in HIV-1 RNase H domain and nucleoside reverse transcriptase inhibitors resistance mutations in naïve and pre-treated HIV infected patients.
Journal of medical virology 2007;79(3):207-11.
2007: Stephanie Dominguez; Jade Ghosn; Gilles Peytavin; Hassane Izzedine; Marc Wirden; Nadine Ktorza; M Miller; Camille Aubron-Olivier; Aldo Trylesinski; Vincent Calvez; Gilbert Deray; Christine Katlama
Efficacy and safety of tenofovir double-dose in treatment-experienced HIV-infected patients: the TENOPLUS study.
Journal of medical virology 2007;79(2):105-10.
2007: Marie-Laure Chaix; Loic Desquilbet; Diane Descamps; Dominique Costagliola; Christiane Deveau; Julie Galimand; Cécile Goujard; Anne Signori-Schmuck; Véronique Schneider; Catherine Tamalet; Isabelle Pellegrin; Marc Wirden; Bernard Masquelier; Françoise Brun Vezinet; Christine Rouzioux; Laurence Meyer
Response to HAART in French patients with resistant HIV-1 treated at primary infection: ANRS Resistance Network.
Antiviral therapy 2007;12(8):1305-10.
2007: Anne-Geneviève Marcelin; Philippe Flandre; Carmen de Mendoza; Bénédicte Roquebert; Gilles Peytavin; Luisa Valer; Marc Wirden; Sarah Abbas; Christine Katlama; Vincent Soriano; Vincent Calvez
Clinical validation of saquinavir/ritonavir genotypic resistance score in protease-inhibitor-experienced patients.
Antiviral therapy 2007;12(2):247-52.
2006: Marc Wirden; Bénédicte Roquebert; Anne Derache; Anne Simon; Claudine Duvivier; Jade Ghosn; Stephanie Dominguez; Véronique Boutonnet; Zaina Ait-Arkoub; Christine Katlama; Vincent Calvez; Anne-Geneviève Marcelin
Risk factors for selection of the L74I reverse transcriptase mutation in human immunodeficiency virus type 1-infected patients.
Antimicrobial agents and chemotherapy 2006;50(7):2553-6.
2006: Bénédicte Roquebert; Isabelle Malet; Marc Wirden; Roland Tubiana; Marc-Antoine Valantin; Anne Simon; Christine Katlama; Gilles Peytavin; Vincent Calvez; Anne-Geneviève Marcelin
Role of HIV-1 minority populations on resistance mutational pattern evolution and susceptibility to protease inhibitors.
AIDS (London, England) 2006;20(2):287-9.
2006: Anne-Geneviève Marcelin; Philippe Flandre; Andre Furco; Marc Wirden; Jean-Michel Molina; Vincent Calvez
Impact of HIV-1 reverse transcriptase polymorphism at codons 211 and 228 on virological response to didanosine.
Antiviral therapy 2006;11(6):693-9.
2006: Ana Canestri; Jade Ghosn; Marc Wirden; Françoise Marguet; Nadine Ktorza; Imane Boubezari; Stephanie Dominguez; Philippe Bossi; Eric Caumes; Vincent Calvez; Christine Katlama
Foscarnet salvage therapy for patients with late-stage HIV disease and multiple drug resistance.
Antiviral therapy 2006;11(5):561-6.
2005: Jade Ghosn; Marc Wirden; Nadine Ktorza; Gilles Peytavin; Hocine Aït-Mohand; Luminita Schneider; Stephanie Dominguez; François Bricaire; Vincent Calvez; Dominique Costagliola; Christine Katlama
No benefit of a structured treatment interruption based on genotypic resistance in heavily pretreated HIV-infected patients.
AIDS (London, England) 2005;19(15):1643-7.
2005: Hassane Izzedine; Marc Wirden; Vincent Launay-Vacher
Viral load and HIV-associated nephropathy.
The New England journal of medicine 2005;353(10):1072-4.
2005: Marc Wirden; Anne-Geneviève Marcelin; Anne Simon; Myriam Kirstetter; Roland Tubiana; Marc-Antoine Valantin; Luc Paris; Manuela Bonmarchand; Francoise Conan; Laurence Kalkias; Christine Katlama; Vincent Calvez
Resistance mutations before and after tenofovir regimen failure in HIV-1 infected patients.
Journal of medical virology 2005;76(3):297-301.
2005: Anne-Geneviève Marcelin; Philippe Flandre; Juliette Pavie; Nathalie Schmidely; Marc Wirden; Olivier Lada; Dan Chiche; Jean-Michel Molina; Vincent Calvez
Clinically relevant genotype interpretation of resistance to didanosine.
Antimicrobial agents and chemotherapy 2005;49(5):1739-44.
2005: Diane Descamps; Marie-Laure Chaix; Patrice André; Véronique Brodard; Jacqueline Cottalorda; Christiane Deveau; Martine Harzic; Didier Ingrand; Jacques Izopet; Evelyne Kohli; Bernard Masquelier; Said Mouajjah; Pierre Palmer; Isabelle Pellegrin; Jean-Christophe Plantier; Cécile Poggi; Sylvie Rogez; Annick Ruffault; Véronique Schneider; Anne Signori-Schmück; Catherine Tamalet; Marc Wirden; Christine Rouzioux; Françoise Brun Vezinet; Laurence Meyer; Dominique Costagliola
French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001-2002.
Journal of acquired immune deficiency syndromes (1999) 2005;38(5):545-52.
2005: Marc Wirden; Isabelle Malet; Anne Derache; Anne-Geneviève Marcelin; Bénédicte Roquebert; Anne Simon; Myriam Kirstetter; Laurence Morand Joubert; Christine Katlama; Vincent Calvez
Clonal analyses of HIV quasispecies in patients harbouring plasma genotype with K65R mutation associated with thymidine analogue mutations or L74V substitution.
AIDS (London, England) 2005;19(6):630-2.
2005: Philippe Flandre; Anne-Geneviève Marcelin; Juliette Pavie; Nathalie Shmidely; Marc Wirden; Olivier Lada; Marie-Charlotte Bernard; Jean-Michel Molina; Vincent Calvez
Comparison of tests and procedures to build clinically relevant genotypic scores: application to the Jaguar study.
Antiviral therapy 2005;10(4):479-87.
2004: Anne-Geneviève Marcelin; Cécile Dalban; Gilles Peytavin; Claire Lamotte; Rachid Agher; Constance Delaugerre; Marc Wirden; Françoise Conan; Sylvie Dantin; Christine Katlama; Dominique Costagliola; Vincent Calvez
Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2004;48(12):4687-92.
2004: Anne-Geneviève Marcelin; Dissou Affolabi; Claire Lamotte; Hocine Ait Mohand; Constance Delaugerre; Marc Wirden; Delphine Voujon; Philippe Bossi; Nadine Ktorza; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Resistance profiles observed in virological failures after 24 weeks of amprenavir/ritonavir containing regimen in protease inhibitor experienced patients.
Journal of medical virology 2004;74(1):16-20.
2004: Marc Wirden; Anne-Geneviève Marcelin; Roland Tubiana; Marc-Antoine Valantin; Jade Ghosn; Claudine Duvivier; Stephanie Dominguez; Luc Paris; Rachid Agher; Gilles Peytavin; Christine Katlama; Vincent Calvez
Virologic outcome after switching from a nucleoside reverse transcriptase inhibitor to tenofovir in patients with undetectable HIV-1 RNA plasma level.
Journal of acquired immune deficiency syndromes (1999) 2004;36(3):876-8.
2004: Christine Katlama; Jade Ghosn; Roland Tubiana; Marc Wirden; Marc-Antoine Valantin; Johan Harmenberg; Göran Mårdh; Bo Oberg; Vincent Calvez
MIV-310 reduces HIV viral load in patients failing multiple antiretroviral therapy: results from a 4-week phase II study.
AIDS (London, England) 2004;18(9):1299-304.
2004: Bernard Masquelier; Catherine Tamalet; Brigitte Montès; Diane Descamps; Gilles Peytavin; Laurence Bocket; Marc Wirden; Jacques Izopet; Véronique Schneider; Virginie Ferré; Annick Ruffault; Pierre Palmer; Aldo Trylesinski; M Miller; Françoise Brun-Vézinet; Dominique Costagliola
Genotypic determinants of the virological response to tenofovir disoproxil fumarate in nucleoside reverse transcriptase inhibitor-experienced patients.
Antiviral therapy 2004;9(3):315-23.
2004: Marc Wirden; Constance Delaugerre; Anne-Geneviève Marcelin; Nadine Ktorza; Hocine Ait Mohand; Stephanie Dominguez; Luminita Schneider; Jade Ghosn; Michele Pauchard; Dominique Costagliola; Christine Katlama; Vincent Calvez
Comparison of the dynamics of resistance-associated mutations to nucleoside reverse transcriptase inhibitors, nonnucleoside reverse transcriptase inhibitors, and protease inhibitors after cessation of antiretroviral combination therapy.
Antimicrobial agents and chemotherapy 2004;48(2):644-7.
2004: Anne-Geneviève Marcelin; Constance Delaugerre; Marc Wirden; Pedro Viegas; Anne Simon; Christine Katlama; Vincent Calvez
Thymidine analogue reverse transcriptase inhibitors resistance mutations profiles and association to other nucleoside reverse transcriptase inhibitors resistance mutations observed in the context of virological failure.
Journal of medical virology 2004;72(1):162-5.
2003: Marc Wirden; Anne Simon; Luminita Schneider; Roland Tubiana; Luc Paris; Anne-Geneviève Marcelin; Constance Delaugerre; Mayeule Legrand; Serge Herson; Gilles Peytavin; Christine Katlama; Vincent Calvez
Interruption of nonnucleoside reverse transcriptase inhibitor (NNRTI) therapy for 2 months has no effect on levels of human immunodeficiency virus type 1 in plasma of patients harboring viruses with mutations associated with resistance to NNRTIs.
Journal of clinical microbiology 2003;41(6):2713-5.
2003: Anne-Geneviève Marcelin; Claire Lamotte; Constance Delaugerre; Nadine Ktorza; Hocine Ait Mohand; Raquel Cacace; Manuela Bonmarchand; Marc Wirden; Anne Simon; Philippe Bossi; François Bricaire; Dominique Costagliola; Christine Katlama; Gilles Peytavin; Vincent Calvez
Genotypic inhibitory quotient as predictor of virological response to ritonavir-amprenavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.
Antimicrobial agents and chemotherapy 2003;47(2):594-600.
2003: Jade Ghosn; Claire Lamotte; Hocine Ait Mohand; Marc Wirden; Rachid Agher; Luminita Schneider; François Bricaire; Claudine Duvivier; Vincent Calvez; Gilles Peytavin; Christine Katlama
Efficacy of a twice-daily antiretroviral regimen containing 100 mg ritonavir/400 mg indinavir in HIV-infected patients.
AIDS (London, England) 2003;17(2):209-14.
2002: Roland Tubiana; Jade Ghosn; Marcio De-Sa; Marc Wirden; Agnès Gautheret-Dejean; François Bricaire; Christine Katlama
Warning: antiretroviral treatment interruption could lead to an increased risk of HIV transmission.
AIDS (London, England) 2002;16(7):1083-4.
2001: Anne-Geneviève Marcelin; Catherine Milliancourt; Nicolas Dupin; Marc Wirden; Jean-Marie Huraux; Henri Agut; Vincent Calvez
Effects of cyclosporine and hydrocortisone on Kaposi's sarcoma-associated herpesvirus genome replication and cell apoptosis induction.
Transplantation 2001;72(10):1700-3.